Nomination Committee appointed for Qlife Holding's Annual General Meeting 2023
In accordance with the decision at Qlife Holding's Annual General Meeting 2022, the company's Chairman of the Board has convened a Nomination Committee to prepare proposals for the Company's Annual General Meeting 2023.
The Nomination Committee consists of the following persons, who together represent approximately 24 percent of the company's shares and votes.
- Anita Otterheim Hjalmarsson, appointed by Thomas Warthoe,
- John Moll, appointed by Lars Bangsgaard,
- Peter Warthoe, representing own shares, and
- Mette Gross, Chairman of the Board.
The Nomination Committee's proposal will be presented in the notice convening the Annual General Meeting 2023 and on the company's website, www.qlifeholding.com.
Shareholders who wish to submit proposals to the Nomination Committee are welcome to contact the Nomination Committee at the company's address, Redaregatan 48, 252 36 Helsingborg. In order for the Nomination Committee to be able to consider a proposal, the proposal must have been received in due time before the Annual General Meeting, and no later than 6th February 2023.
For more information please contact:
Mette Gross, Chair Qlife Holding AB
E-mail: mette.gross@lehdab.com
Tel. No.: +46 (0)73-517 85 25
Qlife is a medical device company that seeks to revolutionize the clinical biomarker market for whole blood testing by taking it out of the lab and into the homes. This will facilitate easy access to blood sample results and in turn facilitate increased monitoring of parameters that enables care improvement.
Shares for Qlife are being traded on Nasdaq First North Growth Market in Stockholm with G&W Fondkommission as certified advisor (phone: +46 (0) 8-503 000 50, e-mail: ca@gwkapital.se).
Read more on Egoo.health, Qlifeholding.com or follow us on LinkedIn.